Fig. 2From: Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trialTotal body water analysis by bioimpedance vectors. The bumetanide plus placebo group is shown in blue (control group), and the bumetanide plus chlorthalidone group is shown in red (intervention group). A There was decreased volume overload in liters of TBW on Day 7 [intervention: -2.5 (95% CI, -3.6 to -1.5) vs. control: -0.59 (95% CI, -1.8 to 0.67), p = 0.003] and Day 30 [intervention: -5.3 (95% CI, -8.6 to -1.95) vs. control: -0.07 (95% CI, -1.02 to 0.87) p = 0.016]. B There was a decrease in ECW on Day 7 [intervention: -1.58 (95% CI, -1.95 to -1.2) vs. control: -0.43 (95% CI, -1.2 to 0.31) p < 0.001] and Day 30 [intervention: -3.05 (95% CI, -4.47 to –1.62) vs. control: -0.15 (95% CI, -0.8 to -0.5), p < 0.000]. C There was a reduction in the ECW/TBW ratio on Day 7 [intervention: -1.29 (95% CI, -2.32 to -0.25) vs. control: -0.72 (95% CI, -1.64 to 0.20), p = 0.384] and Day 30 [intervention: -4.38 (95% CI, -7.8 to -0.92) vs. control: -0.24 (95% CI, -1 to 0.52), p = 0.018]Back to article page